US 12,173,278 B2
Mutants of paenibacillus and methods for their use
Jennifer Anne Collins, Dixon, CA (US); Jesus F. Sanchez, Woodland, CA (US); James L. Waller, West Sacramento, CA (US); Bjorn A. Traag, Walnut Creek, CA (US); Sara K. Hotton, Davis, CA (US); and Tony J. Tegeler, West Sacramento, CA (US)
Assigned to Bayer CropScience LP, St. Louis, MO (US)
Appl. No. 17/054,951
Filed by Bayer CropScience LP, St. Louis, MO (US)
PCT Filed May 8, 2019, PCT No. PCT/US2019/031264
§ 371(c)(1), (2) Date Nov. 12, 2020,
PCT Pub. No. WO2019/221988, PCT Pub. Date Nov. 21, 2019.
Claims priority of provisional application 62/671,067, filed on May 14, 2018.
Prior Publication US 2021/0244031 A1, Aug. 12, 2021
Int. Cl. C12N 1/20 (2006.01); A01N 63/25 (2020.01); C07K 14/195 (2006.01); C12R 1/01 (2006.01)
CPC C12N 1/20 (2013.01) [A01N 63/25 (2020.01); C12N 1/205 (2021.05); C12R 2001/01 (2021.05)] 18 Claims
 
1. A composition comprising a biologically pure culture of a fusaricidin-producing Paenibacillus sp. strain comprising a mutant DegU lacking a functional receiver domain or a functional DNA binding domain and/or a mutant DegS lacking a functional single binding domain or a functional ATPase domain,
wherein the mutant DegU and/or the mutant DegS result in a liquid culture of the Paenibacillus sp. strain with decreased viscosity compared to a liquid culture of a Paenibacillus sp. strain comprising a wild-type DegU and a wild-type DegS.